OncoMatch/Clinical Trials/NCT06794086
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Is NCT06794086 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including PD-1 Monoclonal Antibody and Chemotherapy for colorectal cancer.
Treatment: PD-1 Monoclonal Antibody · Chemotherapy — To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing high-level evidence-based medical evidence for the use of SBRT combined with PD-1 inhibitors in the treatment of unresectable colorectal cancer liver metastasis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Biomarker criteria
Required: Mismatch-repair proficient (pMMR / MSS)
Patients with pMMR/MSS colorectal adenocarcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Exception: no prior radiotherapy for liver metastases, or liver tissue near planned irradiation site not previously irradiated
Patients who have not previously received radiotherapy for liver metastases, or whose liver tissue near the planned irradiation site has not been previously irradiated
Cannot have received: anti-PD-1 therapy
History of prior treatment with anti-PD-1, PD-L1, PD-L2, CTLA-4, or any other specific T-cell costimulatory or checkpoint pathway-targeted therapies
Lab requirements
Blood counts
peripheral blood counts within allowable ranges (tested within 15 days before the start of treatment)
Kidney function
renal function within allowable ranges (tested within 15 days before the start of treatment)
Liver function
Child-Pugh score Class A; at least 700 cc of liver volume outside the treatment area
Cardiac function
no severe ECG abnormalities or active coronary artery disease within 12 months before study entry, severe/unstable angina, newly diagnosed angina or myocardial infarction, or NYHA Class II or higher congestive heart failure
Peripheral blood counts and liver and renal function within allowable ranges (tested within 15 days before the start of treatment); Child-Pugh score Class A; Presence of severe ECG abnormalities or active coronary artery disease within 12 months before study entry, severe/unstable angina, newly diagnosed angina or myocardial infarction, or New York Heart Association (NYHA) Class II or higher congestive heart failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06794086 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, anti-PD-1 therapy disqualifies patients from enrollment.
Does this trial require MLH1?
Yes, MLH1 proficient MMR is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 proficient MMR is a required biomarker for enrollment.
Does this trial require MSH6?
Yes, MSH6 proficient MMR is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages